Yes. So in terms of base ASPs and opportunities, yes, we clearly are seeing an opportunity there as it relates to what was already contracted as of our last quarterly filing and as of the end of June. As indicated, we have provisions in our contracts. And in some cases, even if provisions are not in our contract, customers are reaching out to us and asking for an opportunity to get U.S. supply, which will enable their value creation on domestic content. And then we have a discussion with them. And appropriately adjust -- amend the contracts or the incremental ASP value, we think, is appropriate for dedicating that that allocation to a particular customer. So that's momentum, and we'll continue to see how it progresses. Like I said, we're in very early innings, but we've got a lot of opportunity to continue to pursue. As it relates to U.S. capacity versus Malaysia, Vietnam, as of now, as we see the horizon sold through 2026 by the end of this year, I see all that volume in Malaysia, India -- excuse me, Malaysia, Vietnam has been committed and sold as part of that overall volume. And we are distinguishing ASPs in a meaningful way for that volume and nowhere near -- it will be substantiated by the difference in the relative cost structure between Malaysia and the U.S. on a landed cost basis. So we are seeing some of that, but it's not -- so far it has not been material. And we'll continue to evaluate it as we move forward to ensure that we can sell through that capacity. And if we find that it's difficult to sell it into the U.S., we'll look to sell and support other markets internationally, such as EU from our Malaysia, Vietnam facilities over time. Look, we know that new capacity is going to come into the market. We believe we're an advantaged established player. We've got a unique initiated technology. We're the partner of choice with a number of key customers here in the U.S. We also firmly believe that CapEx is going to be higher to bring production into the U.S. and the cost is going to be higher to manufacture here in the U.S. Our Series 7 product is a low-cost product relative to Series 6 relative to Series 6 in Ohio, but also relative and competitive with our international factories for Series 6. So we believe we've got a differentiated technology, a low-cost technology. And we also believe that competition to put manufacturing here in the U.S., whether it's at the module level, the cell level or down to the wafer level, that will be a higher cost of product that we still believe we can differentiate ourselves and maintain attractive ASPs even if that were to happen.